Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03000257 · ClinicalTrials.gov registry record · Phase 1

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by AbbVie.

Completed
Registry status
Phase 1
Development phase
182
Enrollment target
20
Study locations

NCT03000257 is a Phase 1 study of Advanced Solid Tumors that has completed, run by AbbVie. The registered enrollment target is 182 participants, roughly in line with the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target. The trial reports 20 study locations across 20 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03000257, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by AbbVie.

COMPLETED
Registry status
Phase 1
Development phase
182 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Venetoclax
  • DRUG ABBV-181
  • DRUG Rovalpituzumab Tesirine

Study Locations (20)

California

  • Moores Cancer Center at UC San Diego /ID# 157374 - La Jolla

Illinois

  • The University of Chicago Medical Center /ID# 157375 - Chicago

North Carolina

  • Carolina BioOncology Institute /ID# 157376 - Huntersville

Texas

  • South Texas Accelerated Research Therapeutics /ID# 157378 - San Antonio

Virginia

  • Virginia Cancer Specialists - Fairfax /ID# 157377 - Fairfax

New South Wales

  • Blacktown Hospital /ID# 167386 - Blacktown

Victoria

  • St Vincent's Hospital Melbourne /ID# 167552 - Fitzroy Melbourne

Western Australia

  • Linear Clinical Research /ID# 170797 - Nedlands

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2016-12-14
Est. Completion 2022-03-29
Phase Phase 1

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03000257

The ClinicalTrials.gov registry entry for NCT03000257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT03000257 reports 20 study locations spanning 20 distinct geographic areas - top geographies include California, Illinois, North Carolina.

Frequently Asked Questions

What is clinical trial NCT03000257 about?

NCT03000257 is a clinical study titled "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors". This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with ...

What is the current status of trial NCT03000257?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 182 participants. The study started on 2016-12-14. Estimated completion is 2022-03-29.

What conditions does trial NCT03000257 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT03000257?

The interventions under investigation include: Venetoclax (DRUG), ABBV-181 (DRUG), Rovalpituzumab Tesirine (DRUG).

Who is sponsoring clinical trial NCT03000257?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03000257 being conducted?

This trial has 20 study locations across California, Illinois, North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.